Here are nine notes:
1. The company’s total revenue was $236.2 million in the second quarter of 2016, up 16.4 percent from $202.9 million during the same period last year.
2. For the second quarter 2016, GAAP and non-GAAP gross profit was $176.5 million and $183.8 million, respectively.
3. Total GAAP operating expenses were $116.4 million for the second quarter this year, as compared to $128.6 million for the same period in 2015.
4. Non-GAAP operating expenses were $146.4 million for the second quarter of 2016, up from $123.5 million for the second quarter 2015.
5. NuVasive reported a GAAP net income of $30.2 million, or $0.57 per share, for the second quarter 2016.
6. The company reported a non-GAAP net income of $20.6 million, or $0.40 per share for this quarter.
7. NuVasive completed the acquisition of Biotronic NeuroNetwork during the second quarter. It combined the service offerings of Biotronic with its impulse monitoring business to form NuVasive Clinical Services.
8. The company expects its full-year 2016 revenue to total approximately $962 million.
9. NuVasive also anticipates an adjusted EBITDA margin of approximately 25.4 percent for 2016.
More articles on devices:
Spineart’s new lumbar interbody systems receive CE Mark: 3 takeaways
Medtronic’s Prestige LP Cervical Disc receives 2-level FDA approval: 6 things to know
Not your father’s spine surgery: Dr. John Peloza on MIS technique growth & its impact
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
